首页 | 本学科首页   官方微博 | 高级检索  
     

头孢呋辛酯干混悬剂人体相对生物利用度研究
引用本文:赵甘霖,张强,孙华东,张大卫,吕万良. 头孢呋辛酯干混悬剂人体相对生物利用度研究[J]. 中国药学杂志, 2001, 36(9): 609-611
作者姓名:赵甘霖  张强  孙华东  张大卫  吕万良
作者单位:北京大学药学院药剂学系,
摘    要:
 目的 考察头孢呋辛酯干混悬剂的人体相对生物利用度及生物等效性,从而评价其临床疗效。方法 本研究以市售的进口头孢呋辛酯片剂(西力欣)为对照,选用20名健康志愿受试者,进行了随机的2周期交叉实验。以HPLC测定血药浓度并计算药动学参数及生物利用度,进而对主要动力学参数进行统计学分析。结果 20名受试者交叉po单剂量头孢呋辛酯干混悬剂和西力欣片(250 mg)后两者的主要药动学参数较接近,头孢呋辛酯干混悬剂的相对生物利用度(F)达92.88%。主要参数的方差分析和双单侧t检验结果表明,头孢呋辛酯干混悬剂和西力欣片的AUC0~inf之间无显著性差异(P>0.05),91%置信区间在81.6%~97.2%之间;两种制剂的cmax之间也无显著性差异(P>0.05),90%置信区间为93.6%~121%。结论 头孢呋辛酯干混悬剂与西力欣片具生物等效性。

关 键 词:头孢呋辛酯  相对生物利用度  生物等效性  高效液相色谱法
文章编号:1001-2494(2001)09-0609-03
收稿时间:2000-01-31;
修稿时间:2000-01-31

Bioavailability of cefuroxime axetii suspension in healthy volunteers
ZHAO Gan-lin,ZHANG Qiang,SUN Hua-dong,ZHANG Da-wei,Lü Wan-liang,. Bioavailability of cefuroxime axetii suspension in healthy volunteers[J]. Chinese Pharmaceutical Journal, 2001, 36(9): 609-611
Authors:ZHAO Gan-lin  ZHANG Qiang  SUN Hua-dong  ZHANG Da-wei  Lü Wan-liang  
Affiliation:Department of Pharmaceutics,School of Pharmaceutical Sciences,Peking University,Beijing 100083,China
Abstract:
OBJECTIVE To determine the bioavailability and bioequivalence of cefuroxime axetil suspension formulation in healthy adult male volunteers.METHODS In a randomized two-period crossover study,20 healthy male volunteers received single 250 mg-dose of suspension and tablet formulations of cefuroxime axetil,respectively,where the tablets were used as the reference.The serum concentrations of cefuroxime were determined by a specific high-performance liquid chromatographic (HPLC) method.The pharmacokinetic parameters of the two preparations and the relative bioavailability of suspensions after oral administration were calculated with statistical analysis.RESULTS Following oral administration of the two preparations,the mean AUC0~inf values of the suspension and tablet formulations were (12.14±2.44) μg·h·mL-1 and (13.65±2.92) μg·h·mL-1,respectively;cmax were (4.68±1.34) μg·mL-1 and (4.44±1.36) μg·mL-1,respectively;tmax were (1.30±0.40) h and (1.75±0.62) h,respectively;MRT were (2.49±0.34) h and (3.01±0.81) h,respectively;t1/2 were (1.07±0.22) h and (1.28±0.53) h,respectively.The relative bioavailability (F) of cefuroxime axecil suspensions was 92.88%.Analysis of variance revealed that there were no significant differences between the two preparations of cefuroxime axetil for the mean AUC0~inf and cmax (P>0.05).Two one-sided “t” test showed that 90% confidence intervals of the mean AUC0~inf and cmax of the suspensions compared with the tablets were over the range of 81.6%~97.2% and 93.6%~121%,respectively.CONCLUSION The suspensions and the tablets were bioequivalent.
Keywords:cefuroxime axetil  bioavailability  bioequivalence  HPLC
本文献已被 CNKI 维普 万方数据 等数据库收录!
点击此处可从《中国药学杂志》浏览原始摘要信息
点击此处可从《中国药学杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号